Keith T. Flaherty

Dr Flaherty is Director of Clinical Research at the Cancer Center at Massachusetts General Hospital, where he was named as the Richard Saltonstall Endowed Chair in Oncology, and Professor of Medicine at Harvard Medical School. Dr. Flaherty's research focuses on the understanding of novel, molecularly targeted therapies in cancer and to define the mechanisms of action and resistance of novel therapies. A pioneer in developing targeted therapies matched to the genetic characteristics of a patient's tumor, Dr. Flaherty led early clinical trials on the development of vemurafenib and trametinib and the dabrafenib/trametinib combination. Dr. Flaherty serves as the Editor-in-Chief of Clinical Cancer Research and serves on the Board of Directors of the American Association for Cancer Research. He is also the Deputy Chair for Biomarker Sciences and the Chair of the Developmental Therapeutics Committee in the Eastern Cooperative Oncology Group, a Scientific Advisory Committee member for the Melanoma Research Foundation, and Past-President of the Society for Melanoma Research. Dr. Flaherty is a founding member of X4 Pharmaceuticals, former Director and Chair of the SAB at Loxo Oncology, a wholly owned subsidiary of Eli Lilly and Co. Dr. Flaherty received his medical degree from Johns Hopkins University. Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital and completed a medical oncology fellowship at the University of Pennsylvania.